1. Home
  2. AREN vs DMAC Comparison

AREN vs DMAC Comparison

Compare AREN & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AREN
  • DMAC
  • Stock Information
  • Founded
  • AREN 2016
  • DMAC 2000
  • Country
  • AREN United States
  • DMAC United States
  • Employees
  • AREN N/A
  • DMAC N/A
  • Industry
  • AREN Medical/Dental Instruments
  • DMAC Biotechnology: Pharmaceutical Preparations
  • Sector
  • AREN Health Care
  • DMAC Health Care
  • Exchange
  • AREN Nasdaq
  • DMAC Nasdaq
  • Market Cap
  • AREN 305.8M
  • DMAC 310.1M
  • IPO Year
  • AREN N/A
  • DMAC N/A
  • Fundamental
  • Price
  • AREN $5.76
  • DMAC $7.09
  • Analyst Decision
  • AREN Strong Buy
  • DMAC Strong Buy
  • Analyst Count
  • AREN 1
  • DMAC 3
  • Target Price
  • AREN $12.00
  • DMAC $12.33
  • AVG Volume (30 Days)
  • AREN 246.9K
  • DMAC 430.9K
  • Earning Date
  • AREN 08-14-2025
  • DMAC 11-12-2025
  • Dividend Yield
  • AREN N/A
  • DMAC N/A
  • EPS Growth
  • AREN N/A
  • DMAC N/A
  • EPS
  • AREN 2.74
  • DMAC N/A
  • Revenue
  • AREN $146,610,000.00
  • DMAC N/A
  • Revenue This Year
  • AREN $29.48
  • DMAC N/A
  • Revenue Next Year
  • AREN $11.72
  • DMAC N/A
  • P/E Ratio
  • AREN $2.06
  • DMAC N/A
  • Revenue Growth
  • AREN 6.81
  • DMAC N/A
  • 52 Week Low
  • AREN $0.56
  • DMAC $3.19
  • 52 Week High
  • AREN $10.05
  • DMAC $7.49
  • Technical
  • Relative Strength Index (RSI)
  • AREN 41.18
  • DMAC 68.97
  • Support Level
  • AREN $5.65
  • DMAC $6.83
  • Resistance Level
  • AREN $6.26
  • DMAC $7.46
  • Average True Range (ATR)
  • AREN 0.44
  • DMAC 0.41
  • MACD
  • AREN -0.07
  • DMAC 0.11
  • Stochastic Oscillator
  • AREN 36.79
  • DMAC 82.98

About AREN The Arena Group Holdings Inc.

The Arena Group Holdings Inc is a tech-powered media company that fuses technology, iconic brands, and marketing to deliver vibrant content and experiences that reach million users each month. The company creates robust digital destinations that delight consumers with powerful journalism, news about things such as favorite sports teams, advice on investing, the inside scoop on personal finance, and the latest on lifestyle essentials. The Company operates in one reportable segment which focuses on a publishing platform. The company generates revenue from Digital and Print, where the majority is generated from Digital. The company owns and operates TheStreet, The Spun, Parade, and Men's Journal and powers more than 320 independent Publisher Partners.

About DMAC DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.

Share on Social Networks: